Management Change27 Apr 2026, 09:07 am
Cohance Lifesciences Appoints Umang Vohra as Executive Chairman & Group CEO
AI Summary
Cohance Lifesciences Ltd has appointed Umang Vohra as Executive Chairman, effective May 1, 2026, and Group CEO, effective May 20, 2026. He succeeds Vivek Sharma, who will remain as an advisor for 9 months to ensure a smooth transition. The appointment is a strategic decision by the Board to leverage Vohra's experience in leading transformations and driving growth. Cohance is a technology-driven CDMO platform specializing in complex chemistry, ADCs, oligonucleotides, advanced API development and performance materials.
Key Highlights
- Umang Vohra appointed as Executive Chairman (May 1, 2026) and Group CEO (May 20, 2026) of Cohance Lifesciences.
- Vivek Sharma steps down as Executive Chairman but will continue as an advisor for 9 months.
- Vohra's appointment aims to drive the next phase of transformation and growth at Cohance.
- Cohance focuses on complex APIs, ADCs, Oligonucleotides, and advanced chemistries.
- Advent highlights Vohra's experience in building and leading large-scale transformations.